Insider filing · INBX

Mark Lappe bought $2.6M of Inhibrx Biosciences (INBX)

Executed Sep 8, disclosed Sep 8, the same day.

Not yet measured: the 21-session window has not closed, or the prices around it are not on record.

ML Mark Lappe Chief Executive Officer profile →

Mark Lappe (Chief Executive Officer) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Inhibrx Biosciences, Inc. (INBX). The largest single filing was $2.6M of INBX (24,500 sh across 5 lots, as filed), executed Sep 8. The median gap between execution and disclosure was 0 days.

INBX Inhibrx Biosciences, Inc. INBX · Healthcare · 7 filings in 24 months ticker →

Healthcare · Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→